Melatonin and Menopause: Impact on Sleep, Bones, and Mood

Melatonin levels shift substantially during the menopausal transition, and supplementing with melatonin may address several menopause-related concerns, though the evidence is stronger for some symptoms than others. The connection between the two runs deeper than most people realize: estrogen and melatonin influence each other directly, so as reproductive hormones fluctuate through perimenopause and beyond, the body’s internal clock chemistry changes in ways that affect sleep, bone density, body composition, and more. Understanding how melatonin behaves during this life stage helps clarify what supplementation can and cannot do.

How Melatonin Changes During the Menopausal Transition

Your body does not simply produce less melatonin in a smooth decline as you age. The pattern through perimenopause is more complicated and somewhat counterintuitive. Research in perimenopausal women aged 40 to 50 found that as estrogen drops, nighttime melatonin actually rises temporarily. A significant inverse relationship between peak melatonin and estradiol levels was observed in this age group, and when postmenopausal women were given oral estrogen, their nighttime melatonin was suppressed. When premenopausal women underwent surgical removal of their ovaries, melatonin production climbed.¹ Animal studies confirmed the same pattern: removing the ovaries in rats led to increased melatonin and enzyme activity, while estrogen implants suppressed both.²

This temporary bump does not last. Over the longer arc from premenopause to postmenopause, total melatonin output drops. One longitudinal study found that premenopausal women had geometric mean urinary melatonin metabolite levels of about 53.5 ng/mL, compared with roughly 37.4 ng/mL in those same women after menopause.³ A separate study tracking women across age brackets found that the steepest single decline, about 41%, occurred between the 30–39 and 40–44 age groups, with another drop of about 35% between the early and late fifties.⁴ That second decline aligns closely with the years just after menopause for most women.

So the trajectory looks something like this: melatonin may spike briefly in perimenopause as estrogen falls, then declines to lower-than-premenopausal levels in the postmenopausal years. This two-phase pattern helps explain why some women report surprisingly disrupted sleep even though their melatonin is technically elevated during early perimenopause. The system is unstable, not simply depleted.

Sleep Quality and Melatonin Supplementation

Sleep disturbances are one of the most common and frustrating menopausal complaints, and melatonin supplements are one of the most popular over-the-counter remedies women reach for. The evidence here is mixed but not discouraging. A systematic review found that melatonin treatment improves brain-wave patterns and subjective sleep quality in postmenopausal women who already have sleep problems.⁵ That qualifier matters: the benefit appears most clearly in women with existing sleep impairment, not in women who sleep reasonably well.

However, a meta-analysis pooling data from randomized controlled trials found that melatonin did not produce a statistically significant improvement in standardized sleep quality scores overall.⁶ The apparent contradiction likely reflects differences in study populations and how sleep was measured. Self-reported sleep quality captured by questionnaires may not always match the improvements visible on EEG recordings, and lumping together women with varying degrees of sleep disruption can wash out benefits seen in the more severely affected subgroups.

Expert consensus positions this way: melatonin can be a reasonable option for menopausal insomnia but is not considered a first-line treatment. Cognitive behavioral therapy for insomnia is rated as the most effective approach for postmenopausal women, and clinical guidance notes that while melatonin is frequently used and may help, the mixed results from trials mean it cannot be broadly recommended just yet.⁷ An integrated care approach suggests melatonin alongside behavioral strategies rather than as a standalone fix.⁸

Hot Flashes and Other Vasomotor Symptoms

Hot flashes follow a circadian rhythm. Research has shown that they peak in the early evening, around 6:25 p.m., and are often preceded by small rises in core body temperature.⁹ Because melatonin helps regulate body temperature and circadian timing, there has been interest in whether supplementation could reduce hot flash frequency or severity.

A double-blind randomized trial in menopausal women found that melatonin significantly improved vasomotor symptom scores, along with psychological, somatic, and sexual symptom dimensions, compared with placebo.¹⁰ The meta-analysis mentioned earlier also noted that melatonin seemed to improve physical symptoms in menopausal women, even while falling short on overall sleep quality and mood measures.¹¹

There is, however, a wrinkle. A trial in breast cancer survivors specifically looking at melatonin’s effect on hot flashes found no significant differences compared with placebo.¹² Breast cancer survivors often experience more severe vasomotor symptoms than the general menopausal population, and many cannot take estrogen-based therapies, so the stakes were especially high. The failure in that trial suggests melatonin is unlikely to be a strong standalone remedy for severe hot flashes. It may contribute modestly when combined with other approaches.

One combination study used soy isoflavones, 8-prenylnaringenin (a phytoestrogen from hops), and melatonin together. Over 12 weeks, postmenopausal women experienced a roughly 60% reduction in total hot flashes and a 76.5% reduction in moderate-to-severe episodes.¹³ Those are striking numbers, but because the supplement was a combination, it is impossible to isolate how much credit goes to melatonin alone versus the phytoestrogens.

Bone Density After Menopause

Bone loss accelerates sharply in the first several years after menopause, and there is growing evidence that melatonin plays a role in bone metabolism beyond its more famous job as a sleep signal. In lab and animal studies, melatonin promotes the activity of bone-building cells while inhibiting bone-resorbing cells. It also appears to protect the bone microenvironment from oxidative stress and inflammation.¹⁴

These mechanisms have been tested in a year-long randomized controlled trial in postmenopausal women with low bone density. Compared with placebo, melatonin increased bone mineral density at the femoral neck by about 1.4%, in a dose-dependent fashion. Women taking 3 mg nightly saw a 2.3% increase at that site, while the 1 mg group showed a non-significant 0.5% bump. The higher dose also improved spine volumetric bone density by about 3.6% and increased a measure of bone thickness in the tibia. Urinary calcium excretion dropped by about 12%, suggesting the body was retaining more calcium in bone.¹⁵

A systematic review across multiple studies confirmed that there is a reasonable body of evidence supporting a favorable effect of melatonin on bone density.¹⁶ These are not replacements for standard osteoporosis therapies, but for women in the earlier stages of bone loss, melatonin supplementation could be a relatively low-risk addition to the toolkit. The dose that consistently showed results in the bone trial was 3 mg nightly, taken for at least a year.

Body Composition Changes

Weight gain and shifting body composition are common complaints during and after menopause, often characterized by increased fat and decreased lean mass. A year-long randomized placebo-controlled trial found that postmenopausal women taking melatonin lost about 6.9% of their fat mass compared with placebo. Lean mass also trended upward, and after adjusting for body mass index, the melatonin group gained about 2.6% more lean mass than the placebo group.¹⁷ The systematic review of melatonin and menopausal health similarly flagged a favorable effect on body mass index.¹⁸

Animal research has explored the mechanism behind these changes. In mouse models of sarcopenic obesity, a condition combining excess fat with muscle wasting, melatonin improved the gut microbiota and boosted short-chain fatty acid production. These changes helped reduce muscle inflammation and oxidative stress while promoting muscle protein synthesis.¹⁹ Whether this specific pathway translates directly to human menopause remains to be confirmed, but it aligns with the body composition improvements seen in the clinical trial.

Mood, Anxiety, and Quality of Life

Perimenopause brings increased rates of depression and anxiety, often compounded by poor sleep. A clinical study of perimenopausal women found that melatonin treatment led to significant decreases in scores measuring depression, anxiety, and sleep quality compared with controls.²⁰ The Iranian randomized trial that showed vasomotor benefits also found significant improvements in the psychological symptom domain.²¹

These results are encouraging, but the meta-analytic evidence is less convincing. When pooling across trials, the overall effect on mood did not reach statistical significance.²² It is likely that the mood improvements some studies reported were driven partly by better sleep. Separating the direct mood effects of melatonin from the downstream benefits of sleeping better is genuinely difficult in this research, and studies have not yet teased the two apart convincingly.

What About Blood Pressure, Cholesterol, and Heart Health

Cardiovascular risk climbs after menopause as the protective effects of estrogen wane. Melatonin has antioxidant and anti-inflammatory properties that prompted researchers to test whether it could improve cardiometabolic markers in postmenopausal women. The results so far have been largely negative. A randomized trial found no significant differences in blood pressure or arterial stiffness after three months of melatonin treatment compared with placebo.²³ A separate trial looking at lipid levels found that melatonin had no meaningful effect on triglycerides, total cholesterol, or LDL cholesterol.²⁴

The systematic review went further and noted some evidence that very-low-density lipoprotein and triglyceride levels may actually increase slightly during melatonin use.²⁵ The increases were not dramatic, but they are worth knowing about if you are taking melatonin long-term and monitoring your lipid panel. In short, melatonin does not appear to offer cardiovascular benefits in postmenopausal women, and treating it as a heart-health supplement would be misguided based on current evidence.

Dosing Patterns and What Seems to Work

Most melatonin supplements sold over the counter in the United States come in doses ranging from 0.5 mg to 10 mg, and many people take far more than what research in menopausal women has studied. The doses tested in clinical trials for menopause-related outcomes tend to cluster around 1 to 5 mg nightly, with 3 mg being the most commonly studied dose. The systematic review noted that doses of 3 mg and above improved menopausal symptoms across one or more domains.²⁶ The bone density trial found clear dose-dependent effects, with 3 mg working and 1 mg not reaching significance.²⁷

Timing also matters. Melatonin works best when taken 30 to 60 minutes before your desired bedtime, mimicking the natural rise that signals your body to prepare for sleep. Taking it too early in the evening or too late can shift your circadian rhythm in ways that worsen rather than help sleep timing. In the United States, melatonin is classified as a dietary supplement, not a drug, which means it is not subject to the same manufacturing standards as pharmaceuticals. Independent testing has found wide variation in the actual melatonin content of commercial products compared with what the label claims. If you are considering long-term use, choosing a brand that has been third-party verified is worth the extra effort.

Melatonin and Breast Cancer Risk

The relationship between melatonin and breast cancer has been studied for decades, and it remains one of the more intriguing aspects of melatonin biology in the context of menopause. Melatonin appears to interact with estrogen signaling through two pathways. It can dampen the hormonal signals that drive estrogen production, and at the tumor cell level, it can interfere with estrogen receptor activation and regulate the enzymes that produce estrogen locally in breast tissue.²⁸ Melatonin can also reduce free radical formation independently of these receptor-mediated effects, potentially lowering cellular damage that leads to mutations.²⁹

Epidemiological evidence has linked higher urinary melatonin levels with lower breast cancer risk in postmenopausal women. Conversely, postmenopausal women working night shifts, who typically have lower melatonin and higher estradiol, appear to face elevated risk.³⁰ This fits the broader body of evidence linking chronic circadian disruption to cancer.

One particularly interesting finding comes from mouse research. Neither melatonin nor estradiol-progesterone hormone therapy alone significantly reduced mammary tumor development, but combined, they significantly repressed tumor formation. The combination also appeared to reduce estrogen-driven stimulation of the uterus, raising the possibility that melatonin could offset some of the risks associated with hormone replacement.³¹ This is animal data and should be treated with appropriate caution, but it points toward a hypothesis that researchers find compelling enough to continue pursuing.

Skin Changes After Menopause

Estrogen loss during menopause accelerates skin aging: the epidermis thins, collagen production drops, and elasticity decreases. Most discussions of melatonin and menopause skip the skin entirely, but there is preliminary evidence worth knowing about. In postmenopausal rats, melatonin treatment increased epidermal thickness, boosted the subcutaneous fat layer, and restored elastic fibers. It also increased dermal thickness and raised the levels of several molecules tied to skin structure and renewal, including type I collagen and fibronectin.³²

This is animal research, and no large human trials have tested melatonin specifically for postmenopausal skin aging. But it fits the broader pattern of melatonin acting as an antioxidant and anti-inflammatory agent in tissues that express melatonin receptors, and skin cells do express them. Topical melatonin formulations exist on the market and are promoted for anti-aging purposes, though the marketing has run well ahead of the clinical evidence. If you are already taking oral melatonin for sleep or other menopausal symptoms, any skin benefits would be a bonus rather than a primary reason to start.